PMID- 35548167
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 8
IP  - 49
DP  - 2018 Aug 2
TI  - Development of a high-throughput and sensitive assay of fusion genes in lung 
      cancer by array-based MALDI-TOFMS.
PG  - 27935-27945
LID - 10.1039/c8ra05165h [doi]
AB  - ALK (anaplastic lymphoma kinase gene), ROS1 (ros proto-oncogene 1) and RET (ret 
      proto-oncogene) fusions are oncogenic drivers in non-small cell lung cancer 
      (NSCLC). Methods like fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC) are highly sensitive but subjectively analyzed, labor 
      intensive, expensive and unsuitable for multiple fusion gene screening. This 
      study aimed to establish a high-throughput, sensitive and cost-effective 
      screening method (array-based matrix-assisted laser desorption/ionization 
      time-of-flight mass spectrometry, array-based MALDI-TOFMS) for ALK, ROS1 and RET 
      fusion detection. This method was established with three fusion gene positive 
      cell lines (H2228, ALK positive; HCC78, ROS1 positive; LC-2/AD, RET positive) and 
      negative samples. Then, 34 clinical samples were selected and detected by Sanger 
      sequencing, next generation sequencing (NGS) and array-based MALDI-TOFMS. The 
      results were compared and analyzed and Sanger sequencing was considered the 
      standard. 7 cases showed ALK fusions, 1 case showed ROS1 fusions, no case showed 
      RET fusions and 4 cases were both ALK and ROS1 fusions. Results showed that 
      array-based MALDI-TOFMS was 100% concordant with Sanger sequencing and NGS 82.3%. 
      In this study, we reported the utility of array-based MALDI-TOFMS in the 
      assessment of ALK, ROS1 and RET fusions in routine lung biopsies of FFPE and 
      fresh tissue specimens. Besides, this method may also be applied to the 
      diagnosis, monitoring and prognosis of illness.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Wu, Han-Tao
AU  - Wu HT
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
FAU - Li, Kun
AU  - Li K
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
FAU - Wang, Gang
AU  - Wang G
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
FAU - Yang, Xue-Xi
AU  - Yang XX
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
FAU - Zhu, Anna
AU  - Zhu A
AD  - Guangzhou Darui Biotechnology Co. Ltd. Guangzhou 510665 China.
FAU - Xu, Xu-Ping
AU  - Xu XP
AD  - Guangzhou Darui Biotechnology Co. Ltd. Guangzhou 510665 China.
FAU - Li, Ming
AU  - Li M
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
FAU - Wu, Ying-Song
AU  - Wu YS
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
FAU - Liu, Tian-Cai
AU  - Liu TC
AUID- ORCID: 0000-0002-2985-3766
AD  - Institute of Antibody Engineering, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University Guangzhou 510515 Guangdong P. R. China 
      wg@smu.edu.cn liutc@smu.edu.cn +86-20-37247604 +86-20-62789355.
LA  - eng
PT  - Journal Article
DEP - 20180806
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9087866
COIS- None.
EDAT- 2018/08/06 00:00
MHDA- 2018/08/06 00:01
PMCR- 2018/08/06
CRDT- 2022/05/13 11:22
PHST- 2018/06/16 00:00 [received]
PHST- 2018/07/07 00:00 [accepted]
PHST- 2022/05/13 11:22 [entrez]
PHST- 2018/08/06 00:00 [pubmed]
PHST- 2018/08/06 00:01 [medline]
PHST- 2018/08/06 00:00 [pmc-release]
AID - c8ra05165h [pii]
AID - 10.1039/c8ra05165h [doi]
PST - epublish
SO  - RSC Adv. 2018 Aug 6;8(49):27935-27945. doi: 10.1039/c8ra05165h. eCollection 2018 
      Aug 2.